FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
Sara Caratelli(National Academies of Sciences, Engineering, and Medicine), Giuseppe Sconocchia(National Academies of Sciences, Engineering, and Medicine), Roberto Arriga(University of Rome Tor Vergata), Soldano Ferrone(Massachusetts General Hospital), Luca Maurillo(University of Rome Tor Vergata), Davide Lauro(University of Rome Tor Vergata), Giulia Lanzilli(Istituto di Farmacologia Traslazionale), Maria Ilaria Del Principe(University of Rome Tor Vergata), Tommaso Sconocchia(Istituto di Farmacologia Traslazionale), Andrea Coppola(University of Rome Tor Vergata), Adriano Venditti(University of Rome Tor Vergata), Francesco Buccisano(University of Rome Tor Vergata)
Cited by 75
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k